People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.
Structured Abstract
Background
While adjuvant chemotherapy is recommended in patients with stage III colon cancer, its role in stage II disease is unclear. In treating 100 stage II patients with adjuvant chemotherapy, three or four will benefit, while others will suffer significant adverse effects. Research is underway to improve this decisionmaking. Gene expression profiling (GEP) is one of the techniques being studied.
Purpose
The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.
Methods
The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.
Findings
The objective of this Technical Brief is to provide a summary of the state of the science on use of GEP in predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage II colon cancer. This Brief also summarizes key uncertainties.
Conclusion
Although information is emerging about use of GEP assays to inform the decision about use of adjuvant chemotherapy in patients with stage II colon cancer, studies to date have not provided the type of information needed to address major uncertainties.
